Dataset related to article "Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cance"

This record contains raw data related to article “Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cance" <strong>Introduction: </strong>In the context of metastatic breast cancer, dissemination to the liver is a frequent occurrence. We aimed to evaluate the outcome and toxicity of metastatic breast cancer with liver oligometastases treated with metastases-directed therapies (MDTs), including surgery, stereotactic body radiation therapy, or thermal ablation (radiofrequency or microwaves). <strong>Patients and methods: </strong>We included patients with diagnosis of 1 to 5 liver metastases. Selection criteria included also age &gt; 18 years; Eastern Cooperative Oncology Group performance status 0 to 2; absence of extra-hepatic disease or other controlled metastatic sites. Endpoints were liver progression-free survival (LPFS), progression-free survival (PFS), and overall survival. <strong>Results: </strong>A total of 72 patients were included. Previous local treatments were performed in 13 (18.1%) patients, whereas systemic therapy was used in 81.9% of cases. Treatment of choice was stereotactic body radiation therapy in 54 (75%) patients followed by surgery (13 patients; 18%) and thermal ablation (5 patients; 7%). With a median follow-up of 26.2 months, LPFS at 1 and 2 years was 52.4% and 38.8%, respectively. The number of metastases predicted LPFS (hazard ratio [HR], 1.70; P = .004). Rates of PFS were 38.7% and 22% at 1 and 2 years, respectively. Systemic therapy before MDT (HR, 2.89; P = .016) was correlated with PFS. Overall survival at 1 and 2 years was 95.5% and 76.9%, respectively. Human epidermal growth factor receptor 2 status correlated with survival (HR, 1.82; P = .010). <strong>Conclusion: </strong>Combination of systemic therapy with liver MDT in oligometastatic breast cancer results in durable disease control in a significant proportion of patients. Tumor biology, prior treatment, and extent of disease may be useful to guide the decision to add MDT to standard therapy.本数据集包含与研究论文《肝转移定向治疗在寡转移乳腺癌管理中的应用》相关的原始数据。 **引言：** 在转移性乳腺癌的临床背景下，肝脏转移是较为常见的癌灶扩散部位。本研究旨在评估伴肝脏寡转移的乳腺癌患者接受转移定向治疗（metastases-directed therapies, MDTs）的治疗结局与毒性反应，该治疗方案包括外科手术、立体定向体部放疗（stereotactic body radiation therapy）以及热消融（射频消融或微波消融）。 **患者与方法：** 本研究纳入确诊存在1~5枚肝脏转移灶的患者。入组标准还包括：年龄＞18岁；东部肿瘤协作组（Eastern Cooperative Oncology Group）体力状态评分0~2分；无肝外病灶或其他已得到控制的转移部位。研究终点为肝脏无进展生存期（liver progression-free survival, LPFS）、无进展生存期（progression-free survival, PFS）以及总生存期。 **结果：** 本研究共纳入72例患者。其中13例（18.1%）患者曾接受过局部治疗，81.9%的患者接受过全身治疗。首选治疗方案为立体定向体部放疗，共54例（75%），其次为外科手术（13例，18%）与热消融（5例，7%）。中位随访时间为26.2个月，1年和2年的肝脏无进展生存期率分别为52.4%与38.8%。转移灶数量与肝脏无进展生存期显著相关（风险比[hazard ratio, HR]=1.70；P=0.004）。1年和2年的无进展生存期率分别为38.7%与22%。转移定向治疗前接受全身治疗与无进展生存期显著相关（HR=2.89；P=0.016）。1年和2年的总生存率分别为95.5%与76.9%。人类表皮生长因子受体2（human epidermal growth factor receptor 2, HER2）状态与总生存显著相关（HR=1.82；P=0.010）。 **结论：** 对于寡转移乳腺癌患者，全身治疗联合肝脏转移定向治疗可在相当比例的患者中实现持久的疾病控制。肿瘤生物学特征、既往治疗史以及疾病负荷可用于指导是否在标准治疗基础上加用转移定向治疗的临床决策。